Clinical trials: Headache Disorder
Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
- Trial name
- NCT05518123
- Testing
- Rimegepant
- Where
- 111 sites in United States, Australia and 12 more
- Volunteers
- 962 people
- Sponsor
- Pfizer
Migraine Disorders
Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers
The primary objective is to compare the pharmacokinetics (PK) profiles among five NP101 patches in healthy volunteers. The secondary objective is to evaluate the safety of NP101 in healthy volunteers.
- Trial name
- NP101-006 (NCT00720018)
- Testing
- NP101 Sumatriptan Iontophoretic Transdermal Patch
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- NuPathe Inc.
Headache, Migraine
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine
This is a double blind placebo-controlled study which will evaluate the efficacy of bupivacaine compared to saline, delivered by the Tx360® device to the sphenopalatine ganglion (SPG), to treat chronic migraine headache.
- Trial name
- NCT03337620
- Testing
- Tx360
- Where
- 11 sites in United States
- Volunteers
- 174 people
- Sponsor
- Tian Medical Inc.
Migraine
A Study of LY3451838 in Participants With Migraine
The reason for this study is to see if the study drug LY3451838 is safe and effective in participants who have migraine that have not responded to other preventive treatments.
- Trial name
- NCT04498910
- Testing
- LY3451838
- Where
- 9 sites in United States
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by: Subject self-examination skin irritation scores Adverse events Changes in vital signs and ECG parameters The secondary objective is…
- Trial name
- NP101-008 (NCT00792103)
- Testing
- NP101
- Where
- 34 sites in United States
- Volunteers
- 198 people
- Sponsor
- NuPathe Inc.
Migraine
ZAP, US. Zomig for Appropriate for Primary Care
The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMT™ (zolmitriptan) 5.0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5.0 mg is for patients, in treating migraine over a period of 6 months
- Trial name
- NCT00637286
- Testing
- Zolmitriptan
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Migraine
Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Naratriptan Hydrochloride Tablet under fasted conditions.
- Trial name
- NCT01161667
- Testing
- naratriptan hydrochloride
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Migraine, Migraine Headache
Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine
The purpose of this migraine prevention study is to evaluate the efficacy and safety of AST-726 in moderate to severe migraine patients at one of two doses compared to placebo and compared to a baseline period as measured by a…
- Conditions
- Migraine, Migraine Headache, Migraine Disorders, Migraine With Aura
- Trial name
- NCT00285402
- Testing
- AST-726 Low dose, AST-726 High dose
- Where
- 19 sites in Finland, Netherlands and 1 more
- Volunteers
- 198 people
- Sponsor
- Ariston Pharmaceuticals, Inc.
Primary Body Region (Arranged Most Common to Least), Lumbar/SI
ATI Evidence-based Guide Investigating Clinical Services
The goal of this study is to evaluate how standard-of-care outpatient rehabilitation is delivered and how variation in care delivery mechanisms relates to clinical outcomes, service utilization, and value in patients receiving…
- Conditions
- Primary Body Region (Arranged Most Common to Least), Lumbar/SI, Knee, Shoulder
- Trial name
- AEGIS (NCT02285868)
- Where
- United States
- Volunteers
- 4,000,000 people, healthy volunteers welcome
- Sponsor
- ATI Holdings, LLC
Migraine
Treatment for Migraines With an Implantable Device
The purpose of this study is to evaluate the safety and effectiveness of an implantable device for difficult to treat migraine. There are a significant number of patients who have drug refractory migraine and alternative…
- Trial name
- NCT00286078
- Testing
- Precision
- Where
- 15 sites in United States
- Volunteers
- 179 people
- Sponsor
- Boston Scientific Corporation
Migraine, Photophobia
An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack
The purpose of the study is to show the efficacy of a single dose of PRO-513 for treating subjects suffering moderate pain form a migraine attack, with or without aura.
- Conditions
- Migraine, Photophobia, Phonophobia
- Trial name
- NCT00330850
- Testing
- PRO-513
- Where
- 16 sites in United States
- Volunteers
- 650 people
- Sponsor
- ProEthic Pharmaceuticals
Migraine
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the treatment of moderate or severe of migraine.
- Trial name
- NCT07816367
- Testing
- Elismetrep
- Where
- 72 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- TriGemX Bio, Inc.
Migraine Disorders, Migraine
An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO.
- Trial name
- NCT00319137
- Testing
- GW274150
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Migraine Headache
Neurostimulation Device for Treatment of Migraine Headache
This is a single-site, prospective, non-randomized and open label study to investigate the feasibility of home-use CVS for the prevention of episodic migraine headache and specifically to better understand what type of waveform…
- Trial name
- NCT01630044
- Testing
- TNM device
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Scion NeuroStim
Chronic Cluster Headache
REsponse to Combined SONS and ONS in Chronic Cluster headachE
The purpose of this study is to demonstrate the safe use of the PRIMUS System in subjects with chronic cluster headache. This is a single-centre, open label, prospective, first in human study to collect initial clinical data on…
- Trial name
- RESPONSE (NCT05868044)
- Testing
- PRIMUS
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- Salvia BioElectronics
Migraine
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
- Trial name
- NCT04825678
- Testing
- Erenumab
- Where
- 42 sites in United States
- Volunteers
- 240 people
- Sponsor
- Amgen
Migraine
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine.
- Trial name
- OASIS(CM) (NCT03832998)
- Testing
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3
- Where
- 101 sites in United States, Belgium and 11 more
- Volunteers
- 284 people
- Sponsor
- Amgen
Migraine
A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine Headaches
The purpose of this study is to assess the safety and effectiveness of topiramate as compared to placebo for the prevention of headaches in patients with chronic migraine.
- Trial name
- NCT00210912
- Testing
- topiramate
- Volunteers
- 328 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Migraine
MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)
A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.
- Trial name
- NCT00797667
- Testing
- Telcagepant 140 mg, Telcagepant 280 mg
- Volunteers
- 660 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Headache
Ketone for Migraine Prevention
Efficacy of a nutritional ketogenic supplement (NKS) in reducing the number, intensity, and duration of migraine headaches in episodic migraine patients.
- Trial name
- NCT05085483
- Testing
- Nutritional Ketogenic Supplement
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- Société des Produits Nestlé (SPN)